NZ786079A - Treatment of hidradenitis with jak inhibitors - Google Patents
Treatment of hidradenitis with jak inhibitorsInfo
- Publication number
- NZ786079A NZ786079A NZ786079A NZ78607920A NZ786079A NZ 786079 A NZ786079 A NZ 786079A NZ 786079 A NZ786079 A NZ 786079A NZ 78607920 A NZ78607920 A NZ 78607920A NZ 786079 A NZ786079 A NZ 786079A
- Authority
- NZ
- New Zealand
- Prior art keywords
- subject
- use according
- hidradenitis suppurativa
- hidradenitis
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Methods for treating hidradenitis suppurtiva using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK). The compound is [(1S)-2,2-difluorocyclo-propyl][(1R,5S)-3-{ 2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl} -3,8-diazabicyclo[3.2.1]oct-8-yl]methanone.
Claims (8)
1. Use of [(1S)-2,2-difluorocyclo-propyl][(1R,5S){2-[(1-methyl-1H-pyrazol yl)amino]pyrimidinyl}-3,8-diazabicyclo[3.2.1]octyl]methanone, or a pharmaceutically 5 acceptable salt thereof, in the manufacture of a medicament for treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa.
2. The use according to claim 1, wherein the treatment reduces inflammatory nodules, abscess and draining fistulas as measured by the subject’s HiSCR score.
3. The use according to claim 1, wherein the treatment reduces the median size of the subject’s hidradenitis suppurativa lesions.
4. The use according to claim 1, wherein the treatment increases the subject's time to 15 develop new hidradenitis suppurativa lesions.
5. Use of [(1S)-2,2-difluorocyclo-propyl][(1R,5S){2-[(1-methyl-1H-pyrazol yl)amino]pyrimidinyl}-3,8-diazabicyclo[3.2.1]octyl]methanone, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hidradenitis suppurtiva 20 in a human subject having lesions associated with hidradenitis suppurativa, wherein the medicament is to be administered to the subject in need thereof in an amount effective to treat a symptom of hidradenitis suppurativa in the subject.
6. The use according to claim 5, wherein said effective amount is about 0.01 to about 25 100 mg/kg of body weight/day, in a single dose or as divided doses administered two, three or four times per day.
7. The use according to claim 1, substantially as herein described with reference to any example thereof.
8. The use according to claim 5, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899133P | 2019-09-11 | 2019-09-11 | |
| PCT/IB2020/058333 WO2021048736A1 (en) | 2019-09-11 | 2020-09-08 | Treatment of hidradenitis with jak inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ786079A true NZ786079A (en) | 2025-10-31 |
| NZ786079B2 NZ786079B2 (en) | 2026-02-03 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| US12569487B2 (en) | 2026-03-10 |
| AR119942A1 (en) | 2022-01-19 |
| ES3019413T3 (en) | 2025-05-20 |
| TW202123940A (en) | 2021-07-01 |
| IL291146B1 (en) | 2026-08-01 |
| EP4028007A1 (en) | 2022-07-20 |
| JP2021042204A (en) | 2021-03-18 |
| CA3153676A1 (en) | 2021-03-18 |
| US20250032492A1 (en) | 2025-01-30 |
| IL291146A (en) | 2022-05-01 |
| BR112022004221A2 (en) | 2022-05-31 |
| KR20220059519A (en) | 2022-05-10 |
| CN114667148A (en) | 2022-06-24 |
| EP4028007B1 (en) | 2025-03-26 |
| WO2021048736A1 (en) | 2021-03-18 |
| AU2020347561A1 (en) | 2022-04-14 |
| TWI846947B (en) | 2024-07-01 |
| MX2022002995A (en) | 2022-06-02 |
| MX428336B (en) | 2025-11-13 |
| AU2020347561B2 (en) | 2026-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| HRP20240082T1 (en) | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases | |
| FI3157527T3 (en) | Ezh2 inhibitors for treating lymphoma | |
| JP2014515373A5 (en) | ||
| RU2013121788A (en) | HIV REPLICATION INHIBITORS | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| RU2015102772A (en) | Benzodiazelipas for small cell lung cancer | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| MX2023003576A (en) | Compound as akt kinase inhibitor. | |
| BR112021025764A2 (en) | Pyrimidine derivative that inhibits the growth of cancer cells and medicinal use thereof | |
| JOP20210320A1 (en) | Methods of treating cancer using prmt5 inhibitors | |
| NZ595901A (en) | Use of allopurinol for the treatment of hand foot skin reaction | |
| JP2012525358A5 (en) | ||
| RU2014143213A (en) | Tyrosine kinase inhibitor compounds and their use | |
| NZ786079B2 (en) | Treatment of hidradenitis with jak inhibitors | |
| WO2011031890A4 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| MX2018005298A (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| RU2012114097A (en) | THERAPEUTIC AGENT AGAINST CHRONIC PAIN | |
| HRP20191927T1 (en) | THERAPEUTIC TREATMENT | |
| AU2017299850A8 (en) | Solid forms of TTK inhibitor | |
| CN104147197A (en) | Medicine for treating tinea pedis and preparation method thereof | |
| CN105079555A (en) | Medicine composition for treating myocardial ischemia | |
| NZ743582A (en) | Treatment of chronic hand eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |